CSIMarket
 
Aligos Therapeutics Inc   (ALGS)
Other Ticker:  
 
 

Aligos Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information



ALGS Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) -21.12 % -7.98 % - -0.55 %
Q / Q Revenue Growth (Q3 MRQ) -52.96 % 7.26 % - -1.18 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 52.6 % -15.07 % - %
Seq. Revenue Growth (for 12 months ending Q3 TTM) -5.03 % -2.2 % - 0.08 %
Revenue 5 Year Average Growth - 9.15 % 10.74 % 11.12 %


ALGS's Growth Comparisons in III. Quarter 2023




Aligos Therapeutics Inc 's sharp decrease of -21.12% in sales in the third quarter from the same quarter a year ago, was much faster than sales decline in the Biotechnology & Pharmaceuticals industry with -7.98%, but less than % no change in the Healthcare sector. Slow third quarter sales in Biotechnology & Pharmaceuticals industry and Healthcare sector, were portrayed in Aligos Therapeutics Inc 's results, which underperformed overall market.

Top-line fell by -52.96% from the second quarter results. Comparing the annual growth, sales of % on average in last five years, to the S & P 500's, including only Businesses with the third quarter 2023 financial results, average yearly sales growth is 11.12%. Aligos Therapeutics Inc grew less than the market.


Growth Rates of ALGS's Income in the third quarter 2023


ALGS Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - -99.56 % -41.68 % 0.59 %
Seq. Operating Income Change (Q3 MRQ) - -97.28 % 37.14 % 7.23 %
Y / Y Operating Income Growth (Q3 TTM) - -52.3 % -26.59 % -9.01 %
Seq. Operating Income Growth (Q3 TTM) - -36.22 % -12.38 % -0.23 %
Operating Income 5 Year Avg. Change - -14.04 % 10.15 % 10.87 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - - -77.97 % 1.83 %
Seq. Income from Cont. Ops. Change (Q3 MRQ) - - 384.2 % 10.6 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - -56.11 % -56.82 % -8.43 %
Seq. Income from Cont. Ops. Change (Q3 TTM) - -52.66 % -32.2 % 0.4 %
Income from Cont. Ops. 5 Year Avg. Change - 19.96 % 23.15 % 2.84 %

ALGS Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - - 7.04 % 7.49 %
Q / Q Net Income Growth (Q3 MRQ) - - 2333.8 % 14.75 %
Y / Y Net Income Change (Q3 TTM) - -54.98 % -32.49 % -6.17 %
Seq. Net Income Change (Q3 TTM) - -52.44 % 3.48 % 1.93 %
Net Income 5 Year Avg. Growth - 19.97 % 23.18 % 3.12 %

ALGS's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - - -77.97 % 1.83 %
Seq. EPS from Cont. Ops. Change (Q3 MRQ) - - 384.2 % 10.6 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Seq. EPS from Cont. Ops. Change (Q3 TTM) - - - 117.26 %
EPS from Cont. Ops. 5 Year Avg. Growth - 3.88 % 23.15 % 2.84 %



ALGS EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - - 7.04 % 2.84 %
Q / Q EPS Net Growth (Q3 MRQ) - - 2333.8 % 14.75 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 60498.58 %
Seq. EPS Net Change (for 12 months ending Q3 TTM) - - - 115.79 %
EPS Net 5 Year Avg. Change - 19.97 % 23.18 % 3.12 %



Aligos Therapeutics Inc reported bottom-line of $ -0.41 in the third quarter, compare to $ -0.44 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry fell by -7.98%, while Healthcare sector increased by 7.04%, and overall market improved by 7.49%.

Bottom-line fell by -52.96% from the second quarter results. Comparing the annual growth, income per share of % on average in last five years, to the S & P 500's, including only Businesses with the third quarter 2023 earnings, average yearly income per share growth is 3.12%. Aligos Therapeutics Inc grew less than the market.

ALGS Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - -64.49 % 4.9 % 25.82 %
Seq. Free Cash Flow Change (Q3 MRQ) - -49.36 % 51.72 % 28.6 %
Y / Y Free Cash Flow Change (Q3 TTM) - -49.98 % -8.46 % -3.04 %
Seq. Free Cash Flow Change (Q3 TTM) - -20.07 % 2.41 % 11.75 %
Free Cash Flow 5 Year Avg. Change - 1.98 % 18.45 % 23.3 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - 8.44 % -
Seq. Net Cash Flow Change (Q3 MRQ) - - - -
Y / Y Net Cash Flow Change (Q3 TTM) - - - -
Seq. Net Cash Flow Change (Q3 TTM) - -23.25 % 17.06 % -
Net Cash Flow 5 Year Avg. Change - - 0.72 % 48.8 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) - 12.75 % 3.34 % 69 %
Seq. Capital Expenditures Change (Q3 MRQ) - -16.35 % 5.51 % 16.39 %
Y / Y Capital Expenditures Change (Q3 TTM) -99.41 % -6.78 % 5.42 % -8.14 %
Seq. Capital Expenditures Change (Q3 TTM) -30 % 2.14 % 0.77 % 18.42 %
Capital Expenditures 5 Year Avg. Change - -5.85 % 9.25 % 8.65 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com